Literature DB >> 22556382

Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.

Loreto Rojas1, Eleonora Bunsow, Patricia Muñoz, Emilia Cercenado, Marta Rodríguez-Créixems, Emilio Bouza.   

Abstract

BACKGROUND: Recent studies have reported a greater probability of vancomycin treatment failure in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections caused by strains with a vancomycin MIC ≥ 1.5 mg/L. However, previous reports included patients treated without adjustments based on vancomycin serum levels and with different methods to evaluate MICs, which may render different results.
METHODS: Over a 5 year period (2005-09), vancomycin MICs were determined for 361 MRSA isolates recovered from 309 patients with bloodstream infection using microdilution and the Etest simultaneously. The relationship between the vancomycin MICs determined by each method was assessed. To assess the outcome of patients treated with vancomycin, 104 patients for whom serum vancomycin levels had been determined were selected.
RESULTS: The percentage of MRSA strains with MIC values ≥ 1.5 mg/L according to the Etest was 66.5% compared with only 3.6% according to microdilution. No correlation between mortality and any MIC value obtained with either method was observed, independently of the vancomycin serum levels measured.
CONCLUSIONS: There is a poor correlation between vancomycin MIC values obtained by microdilution and by Etest. No association between mortality rate and any MIC value was observed, not even in patients with suboptimal vancomycin trough serum levels. These data do not support replacing or complementing the standard microdilution test with the Etest for determination of MICs of vancomycin in microbiology laboratories.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22556382     DOI: 10.1093/jac/dks128

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Dissecting the mechanisms of linezolid resistance in a Drosophila melanogaster infection model of Staphylococcus aureus.

Authors:  Lorena Diaz; Dimitrios P Kontoyiannis; Diana Panesso; Nathaniel D Albert; Kavindra V Singh; Truc T Tran; Jose M Munita; Barbara E Murray; Cesar A Arias
Journal:  J Infect Dis       Date:  2013-04-01       Impact factor: 5.226

Review 3.  Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus.

Authors:  Fernando Antonanzas; Carmen Lozano; Carmen Torres
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

4.  Vancomycin minimum inhibitory concentrations and lethality in Staphylococcus aureus bacteremia.

Authors:  Felipe Sulla; Daniel T Bussius; Felipe Acquesta; Alessandra Navarini; Suzethe M Sasagawa; Marcelo J Mimica
Journal:  Germs       Date:  2015-06-02

5.  Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.

Authors:  Rocío Falcón; Eva Mateo; Rosa Oltra; Estela Giménez; Eliseo Albert; Ignacio Torres; David Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-06       Impact factor: 3.267

6.  Management of MRSA/GISA, VISA Endocarditis.

Authors:  Cédric Jacqueline; Jocelyne Caillon; David Boutoille
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

7.  Impact of Vancomycin MIC on Treatment Outcomes in Invasive Staphylococcus aureus Infections.

Authors:  Kyoung-Ho Song; Moonsuk Kim; Chung Jong Kim; Jeong Eun Cho; Yun Jung Choi; Jeong Su Park; Soyeon Ahn; Hee-Chang Jang; Kyung-Hwa Park; Sook-In Jung; Nara Yoon; Dong-Min Kim; Jeong-Hwan Hwang; Chang Seop Lee; Jae Hoon Lee; Yee Gyung Kwak; Eu Suk Kim; Seong Yeon Park; Yoonseon Park; Kkot Sil Lee; Yeong-Seon Lee; Hong Bin Kim
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

Authors:  Sebastiaan J van Hal; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2013-03-19       Impact factor: 9.079

9.  Fungal biofilm architecture produces hypoxic microenvironments that drive antifungal resistance.

Authors:  Caitlin H Kowalski; Kaesi A Morelli; Daniel Schultz; Carey D Nadell; Robert A Cramer
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-26       Impact factor: 11.205

10.  Reduced Vancomycin Susceptibility, MRSA and Treatment Failure in Pediatric Staphylococcus aureus Bloodstream Infections.

Authors:  Ethan Canty; Benjamin Carnahan; Tara Curley; Emily Anususinha; Rana F Hamdy; Jessica E Ericson
Journal:  Pediatr Infect Dis J       Date:  2021-05-01       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.